Lars Zender

31.0k total citations · 8 hit papers
164 papers, 15.8k citations indexed

About

Lars Zender is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Lars Zender has authored 164 papers receiving a total of 15.8k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Molecular Biology, 50 papers in Oncology and 36 papers in Immunology. Recurrent topics in Lars Zender's work include Cancer-related Molecular Pathways (20 papers), Virus-based gene therapy research (18 papers) and RNA Interference and Gene Delivery (17 papers). Lars Zender is often cited by papers focused on Cancer-related Molecular Pathways (20 papers), Virus-based gene therapy research (18 papers) and RNA Interference and Gene Delivery (17 papers). Lars Zender collaborates with scholars based in Germany, United States and United Kingdom. Lars Zender's co-authors include Scott W. Lowe, Wen Xue, Carlos Cordon‐Cardo, Valery Krizhanovsky, Gregory J. Hannon, Eva Hernando, Ross A. Dickins, Cornelius Miething, Michael P. Manns and Stefan Kubicka and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Lars Zender

157 papers receiving 15.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A microRNA component of the p53 tumour suppressor network

2007 2.2k citations Wen Xue, Lars Zender et al. profile →
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

2007 1.9k citations Wen Xue, Lars Zender et al. profile →
Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach

2006 861 citations Lars Zender, Wen Xue et al. Cell profile →
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence

2017 831 citations Katharina Wolter, Tae-Won Kang et al. Nature Cell Biology profile →
The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration

2017 479 citations Florian Heinzmann, Lars Zender et al. profile →
Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression

2016 447 citations Tobias Eggert, Katharina Wolter et al. Cancer Cell profile →
The immunological and metabolic landscape in primary and metastatic liver cancer

2021 392 citations Marco Seehawer, Lars Zender et al. profile →
Advances in PET imaging of cancer

2023 134 citations Johannes Schwenck, Dominik Sonanini et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Zender Germany	51	10.0k	4.1k	3.6k	3.0k	2.5k	164	15.8k
Brett P. Monia United States	77	13.9k 1.4×	3.4k 0.8×	3.3k 0.9×	1.7k 0.6×	2.0k 0.8×	274	21.8k
Joseph R. Testa United States	83	14.1k 1.4×	3.9k 0.9×	5.4k 1.5×	1.9k 0.6×	1.1k 0.4×	347	24.5k
H. Shelton Earp United States	71	8.8k 0.9×	3.8k 0.9×	6.2k 1.7×	7.7k 2.5×	2.1k 0.8×	241	21.4k
Kazuaki Takabe United States	60	7.0k 0.7×	2.8k 0.7×	4.3k 1.2×	2.1k 0.7×	960 0.4×	398	12.6k
Ivan Bièche France	76	11.1k 1.1×	5.7k 1.4×	5.9k 1.6×	1.7k 0.6×	698 0.3×	497	20.2k
Paul Dent United States	81	15.6k 1.6×	2.4k 0.6×	7.0k 2.0×	2.1k 0.7×	906 0.4×	388	23.1k
Owen J. Sansom United Kingdom	80	14.4k 1.4×	4.9k 1.2×	8.8k 2.5×	2.8k 0.9×	1.0k 0.4×	311	23.8k
Alexandra Giatromanolaki Greece	65	7.6k 0.8×	5.9k 1.4×	4.2k 1.2×	2.0k 0.7×	646 0.3×	389	15.3k
Keping Xie United States	71	11.0k 1.1×	5.4k 1.3×	5.5k 1.6×	2.0k 0.7×	1.1k 0.5×	210	17.2k
Ruggero De Maria Italy	72	13.1k 1.3×	6.1k 1.5×	9.1k 2.5×	4.0k 1.3×	1.1k 0.5×	257	22.8k

Countries citing papers authored by Lars Zender

Since Specialization

Citations

This map shows the geographic impact of Lars Zender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Zender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Zender more than expected).

Fields of papers citing papers by Lars Zender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Zender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Zender. The network helps show where Lars Zender may publish in the future.

Co-authorship network of co-authors of Lars Zender

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Zender. A scholar is included among the top collaborators of Lars Zender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Zender. Lars Zender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hinterleitner, Clemens, Stephan Singer, Sven Mattern, et al.. (2024). Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies. Clinical Nuclear Medicine. 49(3). 207–214. 8 indexed citations

Schwenck, Johannes, Johann Jacoby, Gerald Reischl, et al.. (2023). Long-term prognostic factors for PRRT in neuroendocrine tumors. Frontiers in Medicine. 10. 1169970–1169970. 16 indexed citations

Schwenck, Johannes, Dominik Sonanini, Walter Ehrlichmann, et al.. (2023). In vivo imaging of CD8⁺ T cells in metastatic cancer patients: first clinical experience with simultaneous [⁸⁹Zr]Zr-Df-IAB22M2C PET/MRI. Theranostics. 13(8). 2408–2423. 10 indexed citations

D’Artista, Luana, Iros Barozzi, Amanda J. Craig, et al.. (2023). MYC determines lineage commitment in KRAS-driven primary liver cancer development. Journal of Hepatology. 79(1). 141–149. 18 indexed citations

Hinterleitner, Clemens, et al.. (2023). Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience. Cancers. 15(17). 4316–4316.

Ade, Carsten P., Apoorva Baluapuri, Ursula Eilers, et al.. (2021). MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer Research. 81(16). 4242–4256. 19 indexed citations

Chau, Ian, Nicolas Penel, Andres O. Soriano, et al.. (2020). Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers. 12(10). 2985–2985. 22 indexed citations

Hölzer, Kerstin, Alessandro Ori‬‬, Amy Cooke, et al.. (2019). Nucleoporin Nup155 is part of the p53 network in liver cancer. Nature Communications. 10(1). 2147–2147. 31 indexed citations

Song, Chun‐Qing, Yingxiang Li, Haiwei Mou, et al.. (2017). Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. DSpace@MIT (Massachusetts Institute of Technology). 1 indexed citations

10.

Martinez-Quetglas, Iris, Roser Pinyol, Daniel Dauch, et al.. (2016). IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology. 151(6). 1192–1205. 100 indexed citations

11.

Hölzer, Kerstin, Elisabeth Drucker, Stéphanie Roessler, et al.. (2016). Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. American Journal Of Pathology. 187(2). 228–235. 29 indexed citations

12.

Eggert, Tobias, Katharina Wolter, Juling Ji, et al.. (2016). Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell. 30(4). 533–547. 447 indexed citations breakdown →

13.

Hoare, Matthew, Yoko Itō, Tae-Won Kang, et al.. (2016). NOTCH1 mediates a switch between two distinct secretomes during senescence. Nature Cell Biology. 18(9). 979–992. 366 indexed citations

14.

Li, Jinyu, Maïa Chanrion, Eric T. Sawey, et al.. (2015). Reciprocal Interaction of Wnt and RXR-α Pathways in Hepatocyte Development and Hepatocellular Carcinoma. PLoS ONE. 10(3). e0118480–e0118480. 12 indexed citations

15.

Zender, Steffen, Irina Nickeleit, Torsten Wüestefeld, et al.. (2013). A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas. Cancer Cell. 23(6). 784–795. 162 indexed citations

16.

Zender, Lars, Augusto Villanueva, Victoria Tovar, et al.. (2010). Cancer gene discovery in hepatocellular carcinoma. Journal of Hepatology. 52(6). 921–929. 147 indexed citations

17.

Ma, Ou, Wei‐Wen Cai, Lars Zender, et al.. (2009). MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma Progression. Cancer Research. 69(6). 2559–2567. 81 indexed citations

18.

Krizhanovsky, Valery, Ross A. Dickins, Stephen Hearn, et al.. (2008). Senescence of Activated Stellate Cells Limits Liver Fibrosis. Cell. 134(1). 190–190. 93 indexed citations

19.

Zender, Lars, et al.. (2006). Late breaking abstracts. Hepatology. 44(S1). 692A–700A. 19 indexed citations

20.

Kühnel, Florian, Lars Zender, Thomas Wirth, et al.. (2003). Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways. Cancer Gene Therapy. 11(1). 28–40. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact